Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12710446 | 0.92 | APP (0.64) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL13998685 | 0.85 | ALDH1A1 (0.59) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL27424623 | 0.84 | NPC1 (0.50) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2244448 | 0.83 | NPC1 (0.58) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL27424130 | 0.82 | NPC1 (0.49) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL27423331 | 0.82 | NPC1 (0.49) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL13998715 | 0.82 | HPGD (0.57) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL27424133 | 0.81 | ALDH1A1 (0.48) | APPNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL12910410 | 0.81 | HPGD (0.56) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL9867688 | 0.80 | SGMS2 (0.55) | NPC1RAB9AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| WO-2009155017-A2 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-4131677-A | Anti-inflammatory oxazolo [5,4-b]pyridines | MERCK & CO., INC. (US) | 1978-12-26 | — | — | US | disclosed |
| US-4038396-A | ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | APBA1, APP, BACE1 | APP 2/4885NPC1 662/4885RAB9A 4035/4885 |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MAOB, MAOA, AANAT | APP 73/4885NPC1 1904/4885RAB9A 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.